rethinkPeptides Search
Menu
Study breakdown

Dapagliflozin Plus Liraglutide: Dual Drug Approach to Cardio-Renal Protection

Animal StudyPreliminary evidence
The takeaway

Combination of SGLT2 inhibitor dapagliflozin and GLP-1 agonist liraglutide showed potential for enhanced cardio-renal protection through complementary mechanisms.

Key finding

Combination of SGLT2 inhibitor dapagliflozin and GLP-1 agonist liraglutide showed potential for enha

What the researchers found

Combination of SGLT2 inhibitor dapagliflozin and GLP-1 agonist liraglutide showed potential for enhanced cardio-renal protection through complementary mechanisms.

Why it matters

These findings have significant implications for peptide-based therapeutic development and clinical practice.

The numbers in context

30 rats total: 6 controls, 24 diabetic rats split into 4 groups. High-fat diet for 4 weeks followed by single-dose streptozotocin to induce diabetes.

How the study worked

Study design and methodology detailed in the full publication.

Who was studied

Male rats with diet and streptozotocin-induced type 2 diabetes

What this study cannot tell us

Study-specific limitations discussed in the full publication. Results should be interpreted within the context of study design.

How to read the evidence

Evidence assessment based on study design detailed in publication.

When this study was published

Published in 2025. Current peptide therapeutic research.

The bigger picture

This study contributes to the expanding understanding of how peptide-based therapeutics can be applied across medical specialties.

Questions still open

  • What are the long-term implications?
  • How do these results compare to existing evidence?
  • What further research is needed?

Common questions

What does this study mean for patients?
Combination of SGLT2 inhibitor dapagliflozin and GLP-1 agonist liraglutide showed potential for enhanced cardio-renal protection through complementary mechanisms.
How reliable are these findings?
Evidence strength depends on study design. Consult the full publication and your healthcare provider for personalized guidance.

Read the original research

The Potential Effect of Dapagliflozin and Liraglutide in Attenuating Cardio-Renal Injuries in Diabetic Rats.

Journal of experimental pharmacology, 17, 467-484

Citation

Albanna, Adel Ali; Ibrahim, Doa'a Anwar; Shamsher, Amani Mohammed; Al-Shawia, Mojahed Ali; Halboup, Abdulsalam. (2025). The Potential Effect of Dapagliflozin and Liraglutide in Attenuating Cardio-Renal Injuries in Diabetic Rats.. Journal of experimental pharmacology, 17, 467-484. https://doi.org/10.2147/JEP.S522053